Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share @Cosmo_Pharma #HealthCare #Earnings #Results #OTC #OTCMarkets #OTCStocks #Investing

Ad hoc announcement pursuant to Art. 53 LR Medtronic deal accounted in 2024, to inject USD 200m cash. FDA approval of GI Genius new enhanced operating system. New GI drug development program announced. Outlook for 2025. Dublin, Ireland--(Newsfile Corp. - March 20, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its preliminary unaudited results for the financial year 2023. ...


http://dlvr.it/T4KzTQ

Comments

Popular posts from this blog

SEC Investor Advisory Committee to Discuss Exempt Offerings and Accredited Investors at September 21 Meeting #Banking #FinancialServices

ICEBERG Financial Announces New Fintech Product and Pre-Launch Institutional Contract #Banking #FinancialServices

Cleantek Industries Inc. Announces a Twelve-Month Extension of Credit Facility #CTEK.CA #CTEK.V #GLKFF #Investing #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Technology